Clinical Trial

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-05; most recent amendment 2025-11-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-15
Trial Details
NCT Number NCT06967610
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Eli Lilly and Company
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Enrollment 40 participants
Start Date 2025-07-15
Primary Completion 2031-06-01 (estimated)
Study Completion 2033-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30